Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNS851 in healthy participants and participants with metabolic disease
NCT07417124Phase 1Recruiting
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SNS851 with Placebo (2 arms). Primary endpoints: Incidence and severity of Treatment-Emergent Adverse Events at 6 months, Incidence of withdrawals due to Adverse Events at 6 months and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
SNS851
Beyond the preview
Go deeper on NCT07417124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07417124.